UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mitochondrial DNA content and methylation in sperm of patients with asthenozoospermia

Journal of assisted reproduction and genetics, 2024-10, Vol.41 (10), p.2795-2805

2024

Volltextzugriff (PDF)

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

The lancet respiratory medicine, 2024-09

2024

Volltextzugriff (PDF)

Updated efficacy of anti-TROP2 ADC ESG401 for first-line metastatic TNBC in phase 1b study

Journal of clinical oncology, 2024-08, Vol.42 (23_suppl), p.2-2

2024

Volltextzugriff (PDF)

Predicting glass transition temperature of polymers by combining molecular dynamics simulations and machine learning techniques

Materials today communications, 2024-08, Vol.40, p.110181, Article 110181

2024

Volltextzugriff (PDF)

The magnesium depletion score is associated with increased likelihood of kidney stone disease among female adults

Journal of trace elements in medicine and biology, 2024-07, Vol.84, p.127432, Article 127432

2024

Volltextzugriff (PDF)

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8502-8502

2024

Volltextzugriff (PDF)

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Cancer immunology, immunotherapy, 2024-05, Vol.73 (7), p.124, Article 124

2024

Volltextzugriff (PDF)

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet respiratory medicine, 2023-07, Vol.11 (7), p.624-636

2023

Volltextzugriff (PDF)

Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9002-9002

2023

Volltextzugriff (PDF)

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.628-639

2023

Volltextzugriff (PDF)

Expert consensus on treatment for stage III non‐small cell lung cancer

Medicine advances (Online), 2023-03, Vol.1 (1), p.3-13

2023

Volltextzugriff (PDF)

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

The Lancet regional health. Western Pacific, 2023-02, Vol.31, p.100617-100617, Article 100617

2023

Volltextzugriff (PDF)

Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21145-e21145

2022

Volltextzugriff (PDF)

IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2650-2650

2022

Volltextzugriff (PDF)

Potassium Storage Performance of UiO-66 Derivatives from First Principles Calculations

Journal of physical chemistry. C, 2022-03, Vol.126 (9), p.4286-4295

2022

Volltextzugriff (PDF)

老年人多维度健康素养与健康相关行为的调查研究

国际护理科学（英文）, 2022, Vol.9 (2), p.203-后插6

2022

Volltextzugriff (PDF)

A Promising Future of Ferroptosis in Tumor Therapy

Frontiers in cell and developmental biology, 2021-06, Vol.9, p.629150-629150

2021

Volltextzugriff (PDF)

Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2589-2589

2021

Volltextzugriff (PDF)

Understanding Health and Social Challenges for Aging and Long-Term Care in China

Research on aging, 2021-03, Vol.43 (3-4), p.127-135

2021

Volltextzugriff (PDF)

Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer

Clinical interventions in aging, 2021-02, Vol.16, p.205

2021

Volltextzugriff (PDF)

Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer (≥49 Years): An Antidepressant-Stratified Analysis

Clinical interventions in aging, 2021-01, Vol.16, p.205-212

2021

Volltextzugriff (PDF)

Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer (≥49 Years): An Antidepressant-Stratified Analysis [Retraction]

Clinical interventions in aging, 2021-01, Vol.16, p.1455-1456

2021

Volltextzugriff (PDF)

FCS-MPC for a single-phase two-stage grid-connected PV inverter

IET power electronics, 2019-04, Vol.12 (4), p.915-922

2019

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)
Tagungsberichte
(3)

Sprache

Englisch
(32)
Chinesisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Mitochondrial DNA content and methylation in sperm of patients with asthenozoospermia

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

Updated efficacy of anti-TROP2 ADC ESG401 for first-line metastatic TNBC in phase 1b study

Predicting glass transition temperature of polymers by combining molecular dynamics simulations and machine learning techniques

The magnesium depletion score is associated with increased likelihood of kidney stone disease among female adults

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial

Expert consensus on treatment for stage III non‐small cell lung cancer

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in first-line advanced squamous non-small cell lung cancer (sqNSCLC): Initial results from a phase Ib study

IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study

Potassium Storage Performance of UiO-66 Derivatives from First Principles Calculations

老年人多维度健康素养与健康相关行为的调查研究

A Promising Future of Ferroptosis in Tumor Therapy

Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors

Understanding Health and Social Challenges for Aging and Long-Term Care in China

Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer

Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer (≥49 Years): An Antidepressant-Stratified Analysis

Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer (≥49 Years): An Antidepressant-Stratified Analysis [Retraction]

FCS-MPC for a single-phase two-stage grid-connected PV inverter

Suchergebnisse filtern